S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:MGEN

Miragen Therapeutics Competitors

$16.44
-0.54 (-3.18 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.12
Now: $16.44
$17.15
50-Day Range
$16.51
MA: $20.20
$24.93
52-Week Range
$4.66
Now: $16.44
$34.05
Volume31,312 shs
Average Volume134,027 shs
Market Capitalization$64.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66

Competitors

Miragen Therapeutics (NASDAQ:MGEN) Vs. XGN, CNTG, CELC, ENZ, BIOC, and ANPC

Should you be buying MGEN stock or one of its competitors? Companies in the industry of "medical laboratories" are considered alternatives and competitors to Miragen Therapeutics, including Exagen (XGN), Centogene (CNTG), Celcuity (CELC), Enzo Biochem (ENZ), Biocept (BIOC), and AnPac Bio-Medical Science (ANPC).

Miragen Therapeutics (NASDAQ:MGEN) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Valuation and Earnings

This table compares Miragen Therapeutics and Exagen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Miragen Therapeutics$4.46 million14.41$-41,870,000.00($20.09)-0.82
Exagen$40.39 million5.73$-12,040,000.00($8.46)-2.16

Exagen has higher revenue and earnings than Miragen Therapeutics. Exagen is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Miragen Therapeutics and Exagen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Miragen Therapeutics01502.83
Exagen00403.00

Miragen Therapeutics currently has a consensus price target of $16.3333, indicating a potential downside of 0.65%. Exagen has a consensus price target of $23.3333, indicating a potential upside of 27.57%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Miragen Therapeutics.

Institutional & Insider Ownership

29.2% of Exagen shares are held by institutional investors. 1.1% of Miragen Therapeutics shares are held by company insiders. Comparatively, 48.9% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Miragen Therapeutics and Exagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Miragen Therapeutics-1,393.50%-141.66%-88.74%
Exagen-39.49%-29.10%-17.88%

Summary

Exagen beats Miragen Therapeutics on 11 of the 13 factors compared between the two stocks.

Miragen Therapeutics (NASDAQ:MGEN) and Centogene (NASDAQ:CNTG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

Miragen Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Centogene has a beta of -2.25, suggesting that its stock price is 325% less volatile than the S&P 500.

Profitability

This table compares Miragen Therapeutics and Centogene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Miragen Therapeutics-1,393.50%-141.66%-88.74%
CentogeneN/AN/AN/A

Institutional & Insider Ownership

15.8% of Centogene shares are held by institutional investors. 1.1% of Miragen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Miragen Therapeutics and Centogene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Miragen Therapeutics01502.83
Centogene00503.00

Miragen Therapeutics currently has a consensus price target of $16.3333, indicating a potential downside of 0.65%. Centogene has a consensus price target of $20.00, indicating a potential upside of 73.01%. Given Centogene's stronger consensus rating and higher possible upside, analysts clearly believe Centogene is more favorable than Miragen Therapeutics.

Valuation and Earnings

This table compares Miragen Therapeutics and Centogene's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Miragen Therapeutics$4.46 million14.41$-41,870,000.00($20.09)-0.82
Centogene$54.64 million4.20$-23,360,000.00($1.46)-7.92

Centogene has higher revenue and earnings than Miragen Therapeutics. Centogene is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Centogene beats Miragen Therapeutics on 9 of the 13 factors compared between the two stocks.

Miragen Therapeutics (NASDAQ:MGEN) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Profitability

This table compares Miragen Therapeutics and Celcuity's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Miragen Therapeutics-1,393.50%-141.66%-88.74%
CelcuityN/A-52.57%-49.69%

Insider and Institutional Ownership

18.6% of Celcuity shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 43.5% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Miragen Therapeutics and Celcuity's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Miragen Therapeutics$4.46 million14.41$-41,870,000.00($20.09)-0.82
CelcuityN/AN/A$-7,360,000.00($0.72)-19.72

Celcuity has lower revenue, but higher earnings than Miragen Therapeutics. Celcuity is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Miragen Therapeutics and Celcuity, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Miragen Therapeutics01502.83
Celcuity00203.00

Miragen Therapeutics currently has a consensus target price of $16.3333, suggesting a potential downside of 0.65%. Celcuity has a consensus target price of $21.50, suggesting a potential upside of 51.41%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than Miragen Therapeutics.

Risk and Volatility

Miragen Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Celcuity has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.

Summary

Celcuity beats Miragen Therapeutics on 9 of the 13 factors compared between the two stocks.

Miragen Therapeutics (NASDAQ:MGEN) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Miragen Therapeutics and Enzo Biochem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Miragen Therapeutics-1,393.50%-141.66%-88.74%
Enzo Biochem-24.36%-27.05%-14.76%

Insider & Institutional Ownership

60.4% of Enzo Biochem shares are held by institutional investors. 1.1% of Miragen Therapeutics shares are held by insiders. Comparatively, 9.4% of Enzo Biochem shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Miragen Therapeutics and Enzo Biochem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Miragen Therapeutics$4.46 million14.41$-41,870,000.00($20.09)-0.82
Enzo Biochem$76.02 million1.84$-28,520,000.00N/AN/A

Enzo Biochem has higher revenue and earnings than Miragen Therapeutics.

Analyst Recommendations

This is a summary of current ratings and target prices for Miragen Therapeutics and Enzo Biochem, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Miragen Therapeutics01502.83
Enzo Biochem0000N/A

Miragen Therapeutics currently has a consensus target price of $16.3333, indicating a potential downside of 0.65%. Given Miragen Therapeutics' higher probable upside, equities research analysts clearly believe Miragen Therapeutics is more favorable than Enzo Biochem.

Risk and Volatility

Miragen Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Summary

Enzo Biochem beats Miragen Therapeutics on 7 of the 12 factors compared between the two stocks.

Miragen Therapeutics (NASDAQ:MGEN) and Biocept (NASDAQ:BIOC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Miragen Therapeutics and Biocept's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Miragen Therapeutics-1,393.50%-141.66%-88.74%
Biocept-237.01%-114.46%-82.15%

Risk and Volatility

Miragen Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Biocept has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Insider & Institutional Ownership

8.2% of Biocept shares are held by institutional investors. 1.1% of Miragen Therapeutics shares are held by insiders. Comparatively, 0.4% of Biocept shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Miragen Therapeutics and Biocept's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Miragen Therapeutics$4.46 million14.41$-41,870,000.00($20.09)-0.82
Biocept$5.53 million14.61$-25,140,000.00($12.20)-0.49

Biocept has higher revenue and earnings than Miragen Therapeutics. Miragen Therapeutics is trading at a lower price-to-earnings ratio than Biocept, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Miragen Therapeutics and Biocept, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Miragen Therapeutics01502.83
Biocept00203.00

Miragen Therapeutics currently has a consensus target price of $16.3333, indicating a potential downside of 0.65%. Biocept has a consensus target price of $20.00, indicating a potential upside of 231.67%. Given Biocept's stronger consensus rating and higher probable upside, analysts clearly believe Biocept is more favorable than Miragen Therapeutics.

Summary

Biocept beats Miragen Therapeutics on 11 of the 14 factors compared between the two stocks.

Miragen Therapeutics (NASDAQ:MGEN) and AnPac Bio-Medical Science (NASDAQ:ANPC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Insider and Institutional Ownership

0.0% of AnPac Bio-Medical Science shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Miragen Therapeutics and AnPac Bio-Medical Science's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Miragen Therapeutics$4.46 million14.41$-41,870,000.00($20.09)-0.82
AnPac Bio-Medical Science$1.56 million47.46$-14,520,000.00($1.62)-4.08

AnPac Bio-Medical Science has lower revenue, but higher earnings than Miragen Therapeutics. AnPac Bio-Medical Science is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Miragen Therapeutics and AnPac Bio-Medical Science, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Miragen Therapeutics01502.83
AnPac Bio-Medical Science0000N/A

Miragen Therapeutics presently has a consensus price target of $16.3333, indicating a potential downside of 0.65%. Given Miragen Therapeutics' higher possible upside, research analysts clearly believe Miragen Therapeutics is more favorable than AnPac Bio-Medical Science.

Profitability

This table compares Miragen Therapeutics and AnPac Bio-Medical Science's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Miragen Therapeutics-1,393.50%-141.66%-88.74%
AnPac Bio-Medical ScienceN/AN/AN/A

Summary

AnPac Bio-Medical Science beats Miragen Therapeutics on 7 of the 12 factors compared between the two stocks.


Miragen Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Exagen logo
XGN
Exagen
1.8$18.29-5.2%$231.41 million$40.39 million-1.49Gap Down
Centogene logo
CNTG
Centogene
1.2$11.56-3.9%$229.59 million$54.64 million-7.92News Coverage
Gap Down
CELC
Celcuity
1.4$14.20-2.7%$146.32 millionN/A-16.71
Enzo Biochem logo
ENZ
Enzo Biochem
0.7$2.92-1.0%$139.85 million$76.02 million-6.79Upcoming Earnings
News Coverage
Biocept logo
BIOC
Biocept
1.2$6.03-3.5%$80.78 million$5.53 million-1.50Gap Down
ANPC
AnPac Bio-Medical Science
0.7$6.61-0.9%$74.04 million$1.56 million-4.08Increase in Short Interest
OpGen logo
OPGN
OpGen
1.3$2.29-3.5%$51.50 million$3.50 million-1.13Analyst Upgrade
Decrease in Short Interest
Gap Down
PMD
Psychemedics
0.9$7.00-1.1%$38.69 million$37.68 million-10.14Upcoming Earnings
Increase in Short Interest
News Coverage
Cancer Genetics logo
CGIX
Cancer Genetics
0.6$6.51-1.4%$26.59 million$7.30 million-3.14Gap Up
AMS
American Shared Hospital Services
0.1$2.80-5.7%$16.13 million$20.60 million-28.00High Trading Volume
Gap Up
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.